Coagulation Factor VIII and IX: The Cornerstone of Hemophilia Care
The treatment of Hemophilia—a hereditary bleeding disorder—was revolutionized by the development of plasma-derived Coagulation Factor Concentrates.
Factor VIII: Used to treat Hemophilia A. Historically, patients died young from internal joint bleeding; today, regular infusions of Factor VIII allow them to lead near-normal lives.
Factor IX: Used to treat Hemophilia B (Christmas Disease).
While recombinant (synthetic) factors are now available, plasma-derived concentrates remain essential for patients who develop "inhibitors" (antibodies against the synthetic factor) and in regions where recombinant technology is cost-prohibitive. These derivatives provide a concentrated, small-volume injection that can be administered at home, preventing the permanent joint damage caused by repeated internal bleeds.